Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC is a phase 2, interventional study registered as NCT07405190 by Massachusetts General Hospital, with a registry enrolment figure of 46 participants, started 2026-05-01 and due to reach its primary completion in 2028-03-01. Interventions recorded: Ivonescimab; carboplatin; pemetrexed. Conditions listed: Lung Cancer (NSCLC); Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer (Non-Small Cell); Lung Cancer - Non Small Cell; Lung Cancer Non Small Cell; Genomic Alterations. Primary outcome: Objective Response Rate (ORR) of Ivonescimab Monotherapy; Objective Response Rate (ORR) of Ivonescimab plus Carboplatin/Pemetrexed. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed advanced or metastatic non-squamous NSCLC not amenable to curative resection or radiation". Sites: United States. No results are recorded here; the registry entry is the source.